S&P 500
7,357.80
-0.44%
Dow Jones
51,945.60
-0.47%
Nasdaq 100
29,082.80
-1.56%
Russell 2000
3,005.17
-0.36%
FTSE 100
10,505.10
-0.38%
Nikkei 225
69,696.60
-2.22%
AbCellera Biologics

ABCL Q2 2025 Earnings

Reported Aug 7, 2025 at 4:27 PM ET · SEC Source

Q2 25 EPS

$-0.12

BEAT +25.00%

Est. $-0.16

Q2 25 Revenue

$17.1M

BEAT +173.69%

Est. $6.2M

vs S&P Since Q2 25

+29.7%

BEATING MARKET

ABCL +44.1% vs S&P +14.4%

Market Reaction

Did ABCL Beat Earnings? Q2 2025 Results

AbCellera Biologics delivered a standout second quarter, posting revenue of $17.08 million, a 133.3% year-over-year jump that cleared the $6.24 million consensus estimate by 173.69%, while its loss per share of $0.12 came in well ahead of the $0.16 a… Read more AbCellera Biologics delivered a standout second quarter, posting revenue of $17.08 million, a 133.3% year-over-year jump that cleared the $6.24 million consensus estimate by 173.69%, while its loss per share of $0.12 came in well ahead of the $0.16 analysts had expected, representing a 25.00% beat. The primary engine behind the revenue acceleration was a dramatic expansion in licensing revenue, which climbed to $10.45 million from just $370,000 a year ago, signaling that partner programs are beginning to generate meaningful downstream returns. Net loss narrowed modestly to $34.73 million as total operating expenses fell to $66.67 million from $100.78 million, aided in part by sharply lower depreciation and impairment charges. Beyond the financials, the quarter marked a genuine operational shift, with AbCellera initiating dosing in a Phase 1 trial of ABCL635 for vasomotor symptoms and launching a second trial for ABCL575 in atopic dermatitis. The company enters the back half of 2025 with roughly $753 million in total available liquidity, and expects initial clinical data from ABCL635 in mid-2026.

Key Takeaways

  • • Licensing revenue increased significantly to $10.4 million from $0.4 million in Q2 2024
  • • Research fees grew to $6.6 million from $5.5 million year-over-year
  • • R&D expenses decreased to $39.2 million from $40.9 million reflecting ongoing optimization
  • • G&A expenses declined to $19.0 million from $20.2 million
  • • Depreciation, amortization, and impairment charges dropped significantly to $5.5 million from $36.5 million
24/7 Wall St

ABCL YoY Financials

Q2 2025 vs Q2 2024, source: SEC Filings

24/7 Wall St

ABCL Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our transition to a clinical-stage biotechnology company.”

— Carl Hansen, Q2 2025 Earnings Press Release

Back to ABCL Stock Page